Table 1.
Baseline demographic and clinical characteristics of the patients.
| Parameter | JIA (n = 62) | Control (n = 32) | p |
|---|---|---|---|
| Median (Range) | Median (Range) | ||
| Age (years) | 12.0 (2–18) | 11.0 (1–18) | 0.48 |
| ESR (mm/h) | 7.5 (2–120) | 4.0 (2.0–20.0) | 0.19 |
| CRP (mg/dL) | 0.0 (0.0–17.9) | 0.0 (0.0–0.16) | 0.30 |
| IgA anti-SARS-CoV-2 (ratio) | 0.37 (0.06–2.9) | 0.37 (0.1–3.58) | 0.69 |
| Positive anti-SARS-CoV-2 IgA | 6 (9.7%) | 3 (9.4%) | 1.0 |
| IgG anti-SARS (ratio) | 0.30 (0.17–1.9) | 0.29 (0.19–1.21) | 0.58 |
| Positive anti-SARS-CoV-2 IgG | 3 (4.8%) | 2 (6.3%) | 1.0 |
| JADAS 71 | 4.9 (0.0–36.0) | ND | ND |
| Active joint number | 1.0 (0.0–25.0) | ||
| PGA | 2.0 (0.0–7.0) | ||
| PhGA | 2.0 (0.0–18.6) | ||
| Treatment | |||
| Biological DMARDs | 30 (48.4%) | ND | ND |
| Adalimumab | 13 (21.0%) | ||
| Etanercept | 11 (17.7%) | ||
| Tocilizumab | 6 (9.7%) | ||
| Conventional synthetic DMARDs | 62 (100%) | ||
| Methotrexate | 48 (77.4%) | ||
| Hydroxychloroquine | 5 (8.1%) | ||
| Sulfasalazine | 14 (22.6%) | ||
| Glucocorticoids * | 16 (25.8%) |
JIA, juvenile idiopathic arthritis; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; JADAS 71, juvenile arthritis disease activity score 71; PhGA, physician global assessment of disease activity; PGA, parent/patient assessment of overall well-being; ND, not determined. DMARDs, disease-modifying antirheumatic drugs; * systemic glucocorticoids (orally, more than to 2 weeks, regardless of the dose).